Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Triple Negative Breast Cancer Guided by ctDNA
NCT07292142Phase 2Not yet recruiting
- Sponsor
- Jewish General Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic fecal microbiota in triple-negative breast cancer (TNBC) (3 arms), sponsored by Jewish General Hospital. Primary endpoints: Safety of combining Fecal Microbial Transplantation (FMT) with immunotherapy/chemotherapy at 20 months and Feasibility of giving FMT at 7 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07292142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292142.